{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:42:03Z","timestamp":1768909323819,"version":"3.49.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Tedizolid was approved by the United States Food and Drug Administration to treat acute bacterial skin and skin structure infections in adults in 2014, and in 2020, United States Food and Drug Administration expanded the approval of tedizolid to treat pediatric patients 12 years of age and older. This study assessed the activity of tedizolid and comparator agents against clinical surveillance isolates collected from pediatric patients with skin and skin structure infection in the United States.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A total of 2747 gram-positive organisms (1 per patient) were collected in 2015 to 2019 from pediatric (\u226417 years old) patients with skin and skin structure infections. The isolates were collected from 33 US medical centers and susceptibility tested against tedizolid and comparators by reference broth microdilution methods. Susceptibility results for main pathogens were stratified by patient age: \u22641 years old (851 isolates), 2 to 5 years old (623), 6 to 12 years old (754) and 13 to 17 years old (519).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>\n                                 <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic> (n = 2163) was the main pathogen recovered from all age groups, followed by \u03b2-hemolytic streptococci (n = 460). Tedizolid inhibited all <jats:italic toggle=\"yes\">S. aureus<\/jats:italic>, including methicillin-resistant <jats:italic toggle=\"yes\">S. aureus<\/jats:italic> (MRSA) isolates (41.0%), regardless of the age group. MRSA rates varied by age group; MRSA was highest among \u22641 years old (45.0%) and lowest in the 13 to 17 years old (32.7%) groups. Linezolid, daptomycin and vancomycin also displayed susceptibility rates of 100% against <jats:italic toggle=\"yes\">S. aureus<\/jats:italic> isolates. Clindamycin (81.3%\u201398.5%), tetracycline (91.6%\u201397.1%) and trimethoprim-sulfamethoxazole (97.0%\u2013100%) susceptibility rates varied among age groups and methicillin resistance profiles. Overall, tedizolid, linezolid, daptomycin and vancomycin inhibited all gram-positive pathogens in this collection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Tedizolid was very active against a large collection of gram-positive pathogens causing skin and skin structure infection in pediatric patients, including MRSA isolates.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003597","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T10:12:38Z","timestamp":1655287958000},"page":"731-735","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Activity of Tedizolid and Comparator Agents Against Gram-positive Isolates Causing Skin and Skin Structure Infections in Pediatric Patients in United States Hospitals (2015\u20132019)"],"prefix":"10.1097","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2734-3754","authenticated-orcid":false,"given":"Cecilia Godoy","family":"Carvalhaes","sequence":"first","affiliation":[{"name":"From the JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7022-6644","authenticated-orcid":false,"given":"Helio Silva","family":"Sader","sequence":"additional","affiliation":[{"name":"From the JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6798-7653","authenticated-orcid":false,"given":"Paul Richard","family":"Rhomberg","sequence":"additional","affiliation":[{"name":"From the JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1782","authenticated-orcid":false,"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"From the JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6902-9763","authenticated-orcid":false,"given":"Sean","family":"DeVries","sequence":"additional","affiliation":[{"name":"From the JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8648-1137","authenticated-orcid":false,"given":"Rodrigo Elisandro","family":"Mendes","sequence":"additional","affiliation":[{"name":"From the JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"E333","DOI":"10.3390\/ph13110333","article-title":"New antibiotics for the treatment of acute bacterial skin and soft tissue infections in pediatrics.","volume":"13","author":"Principi","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1017\/ice.2018.259","article-title":"Epidemiology of Staphylococcus aureus infections in patients admitted to freestanding pediatric hospitals, 2009-2016.","volume":"39","author":"Spaulding","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/INF.0000000000002764","article-title":"Epidemiologic and molecular characteristics of staphylococcus aureus strains isolated from hospitalized pediatric Patients.","volume":"39","author":"Arikan","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/17512433.2019.1693257","article-title":"Pediatric pharmacokinetics of the antibiotics in the access and watch groups of the 2019 WHO model list of essential medicines for children: a systematic review.","volume":"12","author":"Rashed","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/cid\/civ501","article-title":"Tedizolid: the first once-daily oxazolidinone class antibiotic.","volume":"61","author":"Burdette","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/INF.0000000000003010","article-title":"Safety and Efficacy of oral and\/or intravenous tedizolid phosphate from a randomized phase 3 trial in adolescents with acute bacterial skin and skin structure infections.","volume":"40","author":"Bradley","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/INF.0000000000003030","article-title":"Pharmacokinetics and safety of single-dose tedizolid phosphate in children 2 to <12 Years of Age.","volume":"40","author":"Arrieta","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/QCO.0000000000000239","article-title":"Epidemiology and microbiology of skin and soft tissue infections.","volume":"29","author":"Esposito","year":"2016","journal-title":"Curr Opin Infect Dis"},{"issue":"Suppl 4","key":"R12-20250614","doi-asserted-by":"crossref","first-page":"iv2","DOI":"10.1093\/jac\/dkab350","article-title":"Update on the epidemiology of healthcare-acquired bacterial infections: focus on complicated skin and skin structure infections.","volume":"76","author":"Wilcox","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"491","DOI":"10.5811\/westjem.2014.4.20583","article-title":"Clinical management of skin and soft tissue infections in the U.S. Emergency Departments.","volume":"15","author":"Mistry","year":"2014","journal-title":"West J Emerg Med"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jpedsurg.2011.05.008","article-title":"Increasing national burden of hospitalizations for skin and soft tissue infections in children.","volume":"46","author":"Lautz","year":"2011","journal-title":"J Pediatr Surg"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"e718","DOI":"10.1542\/peds.2012-0746","article-title":"Trends in resource utilization for hospitalized children with skin and soft tissue infections.","volume":"131","author":"Lopez","year":"2013","journal-title":"Pediatrics"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1081\/JDI-100100856","article-title":"Prediction of mortality in patients with bacteremia: the importance of pre-existing renal insufficiency.","volume":"22","author":"Shmuely","year":"2000","journal-title":"Ren Fail"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.diagmicrobio.2006.05.009","article-title":"Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).","volume":"57","author":"Moet","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.annemergmed.2007.12.004","article-title":"Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus.","volume":"51","author":"Pallin","year":"2008","journal-title":"Ann Emerg Med"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6809e1","article-title":"Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible staphylococcus aureus bloodstream infections - United States.","volume":"68","author":"Kourtis","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40265-015-0352-7","article-title":"Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.","volume":"75","author":"Zhanel","year":"2015","journal-title":"Drugs"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"e00609","DOI":"10.1128\/AAC.00609-17","article-title":"Five-year summary of In Vitro activity and resistance mechanisms of linezolid against clinically important gram-positive cocci in the United States from the LEADER Surveillance Program (2011 to 2015).","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1089\/mdr.2018.0410","article-title":"In Vitro activity of tedizolid in comparison with other oral and intravenous agents against a collection of community-acquired methicillin-resistant staphylococcus aureus (2014-2015) in the United States.","volume":"25","author":"Pfaller","year":"2019","journal-title":"Microb Drug Resist"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"e00175","DOI":"10.1128\/AAC.00175-20","article-title":"Assessment of Tedizolid In Vitro Activity and resistance mechanisms against a collection of enterococcus spp. causing invasive infections, including isolates requiring an optimized dosing strategy for daptomycin from U.S. and European Medical Centers, 2016 to 2018.","volume":"64","author":"Carvalhaes","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1093\/jac\/dkz278","article-title":"Characterization of Tn6349, a novel mosaic transposon carrying poxtA, cfr and other resistance determinants, inserted in the chromosome of an ST5-MRSA-II strain of clinical origin.","volume":"74","author":"D\u2019Andrea","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/QCO.0000000000000631","article-title":"Role of new antibiotics in the treatment of acute bacterial skin and skin-structure infections.","volume":"33","author":"Bassetti","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1128\/AAC.03684-14","article-title":"Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function.","volume":"59","author":"Flanagan","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:09:59Z","timestamp":1749946199000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003597","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,2]]}}}